CD7 Positive, T - Cell Lymphoma
Conditions
Brief summary
To evaluate the safety and efficacy of autologous hematopoietic stem cell transfer (ASCT) combined with CD7-CART in the treatment of CD7+ TCL
Interventions
DRUGASCT+CD7-CART
Intravenous infusion of CD7-CART 3 days after ASCT
Sponsors
Hebei Taihe Chunyu Biotechnology Co., Ltd
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
ASCT conbined with CD7-CART
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. With the subject's consent and having signed the informed consent form, willing and capable of adhering to the planned visits, study treatment, laboratory tests and other trial procedures; 2. Age 18 to 65 years old, both male and female; 3. Confirmed as T-cell non-Hodgkin's lymphoma type (including T-lymphoblastic lymphoma/leukemia) according to the World Health Organization's classification of hematopoietic and lymphoid tissue tumors (2022), and meeting one of the following three conditions: 1) Newly diagnosed with high-risk factors, such as Ann Arbor stage III/IV, large mass, bone marrow invasion, central nervous system (CNS) invasion, ETP phenotype, RAS activating mutation, TP53 deletion/mutation, etc., as assessed by the investigator; 2) Not achieving PR or better response after induction and consolidation therapy; 3) Patients not considered for allogeneic hematopoietic stem cell transplantation; 4. Confirmed as tumor cells expressing CD7 by histopathology and/or cytology at the time of screening; 5. With appropriate organ function: 1) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN), if the investigator determines that the abnormal ALT and AST are due to the disease (such as liver infiltration or bile duct obstruction), the indicators can be relaxed to ≤ 5 times ULN; 2) Total serum bilirubin ≤ 2 times ULN, except for patients with Gilbert's syndrome; patients with Gilbert's syndrome and total bilirubin ≤ 3 times ULN and direct bilirubin ≤ 1.5 times ULN can be included; 3) Serum creatinine clearance rate ≥ 30 mL/min; 4) International normalized ratio (INR) ≤ 1.5 times ULN, and activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN; 5) Possessing the minimum level of lung reserve, defined as ≤ grade 1 dyspnea (CTCAE v5.0) and non-oxygen-dependent blood oxygen saturation ≥ 92%; 6) Left ventricular ejection fraction ≥ 50% by echocardiography; no clinically significant abnormal electrocardiogram findings; no clinically significant pericardial effusion and pleural effusion. 6. Women of childbearing age have a negative blood/urine pregnancy test within 7 days before infusion. Any male and female patients with fertility must agree to use effective contraceptive methods throughout the study and for at least 2 years after the administration of study treatment. \-
Exclusion criteria
Subjects with one or more of the following are not eligible for this study: 1. History of allergy to any of the components in the cell product; 2. Severe cardiac disease, including but not limited to: Myocardial infarction, cardiac angioplasty, or stenting within 6 months prior to signing the ICF; unstable angina; severe cardiac arrhythmias; History of severe non-ischemic cardiomyopathy; Congestive heart failure (New York Heart Association \[NYHA\] Class III or IV), NYHA score listed in Appendix II 3. Have a history of autologous/allogeneic hematopoietic stem cell transplantation; 4. stroke or seizure within 6 months prior to signing the ICF; 5. Have autoimmune diseases, immunodeficiencies or other diseases that require immunosuppressant treatment; 6. Within 3 years prior to signing the ICF, have malignancies other than T-cell hematologic tumors, except for adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, localized prostate cancer after radical resection, carcinoma in situ of the duct in situ after radical resection, carcinoma in situ of other sites one year after radical resection, and there has been no treatment during the screening period and there is no sign of recurrence; 7. presence of uncontrolled active infection; 8. Unstable systemic diseases judged by the investigator: including but not limited to severe hepatic, renal or metabolic diseases requiring drug treatment; 9. Any of the following within 4 weeks prior to lymphocyte collection: The DNA detection value of hepatitis B virus (HBV) in peripheral blood was higher than the lower limit of detection; Positive for hepatitis C virus (HCV) antibody and positive for peripheral HCV-RNA; positive for human immunodeficiency virus (HIV) antibodies; positive for syphilis antigen or antibody; Positive for CMV-DNA (10) application of prednisone (or equivalent amounts of other corticosteroids) in excess of 5mg/day within 1 week prior to lymphocyte collection; (11) Have used any CAR-T cell products or other genetically modified T-cell therapies; (12) Received CD7-targeted therapy; (13) History of live vaccination within 4 weeks prior to signing the ICF; (14) Have a history of alcoholism, drug abuse, or mental illness; (15) Other situations that the investigator considers unsuitable to participate in this study. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS rate at 1 year after ASCT conbined with CD7-CART | at 1 year after ASCT conbined with CD7-CART | — |
| Incidence and Severity of Adverse Events after ASCT conbined with CD7-CART | during 2 years after ASCT conbined with CD7-CART | Refer to irAE grading standard |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) | during 2 years after ASCT conbined with CD7-CART | Time from first response evaluated by investigator to disease progression or death from any cause |
| Progression-free Survival (PFS) | during 2 years after ASCT conbined with CD7-CART | — |
| MRD negetive rate | at 3 or 6 month after ASCT conbined with CD7-CART | — |
| Tlast | during 1 year after ASCT conbined with CD7-CART | duration of existence of CARgene copy number in peripheral blood |
| Overall Survival (OS) | during 2 years after ASCT conbined with CD7-CART | — |
| Cmax | during 3 month after ASCT conbined with CD7-CART | the peak CARgene copy number in peripheral blood |
| Tmax | during 3 month after ASCT conbined with CD7-CART | time to reach the peak of CARgene copy number in peripheral blood |
| Time to Response (TTR) | during 2 years after ASCT conbined with CD7-CART | Time from CD7-CART infusion to first documentation of response evaluated by investigators |
| AUC(0-28d) | during 28 days after ASCT conbined with CD7-CART | area under curve of CARgene copy number in peripheral blood |
Countries
China
Contacts
Primary ContactLiang Huang, Dr
Outcome results
None listed